FEMMLUX® is a medicinal product used to relieve menopausal symptoms, such as hot flushes and excessive sweating.

This website is intended exclusively for residents of Portugal.
Date of Summary of Product Characteristics (SmPC) approval: July 2020.
Last revision: July 2020

Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist has told you.
Recommended dose:
Women experiencing menopausal symptoms should take one tablet daily. Try to take the tablet at the same time each day (either in the morning or in the evening). Swallow the tablet whole with a glass of water or another liquid. Do not chew the tablet.
Do not exceed the recommended dose.
If you take more than the recommended dose, consult your doctor or another healthcare professional, such as a pharmacist.
If you forget to take FEMMLUX®, do not take a double dose to make up for a forgotten dose. It is not a problem if you forget to take one tablet.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

This website is intended exclusively for residents of Portugal.
Date of Summary of Product Characteristics (SmPC) approval: July 2020.
Last revision: July 2020

Hypersensitivity to the active substance (dry extract of Cimicifuga racemosa) or to any of the excipients (lactose monohydrate, powdered cellulose, colloidal anhydrous silica, magnesium stearate, maize starch, microcrystalline cellulose, sodium starch glycolate (Type A), hypromellose, macrogol 4000, and titanium dioxide (E171)).
Active liver disease or a history of liver disease.
Patients with a history of, or currently undergoing treatment for, oestrogen-dependent tumours.
Lactose intolerance.
Pregnant or breastfeeding women, or women of childbearing potential.
- Children under 18 years of age.


This website is intended exclusively for residents of Portugal.
Date of Summary of Product Characteristics (SmPC) approval: July 2020.
Last revision: July 2020

Talk to your doctor or pharmacist before taking FEMMLUX®:
- if you have a history of persistent menstrual disorders;
- if you are currently taking a medicine containing oestrogens.

Children and adolescents.
This medicine is not indicated for patients under 18 years of age.

(Pregnancy and breast-feeding)
Do not take FEMMLUX® if you are pregnant or breast-feeding.

(Driving and using machines)
No studies on the effects on the ability to drive and use machines have been performed.

(FEMMLUX® contains lactose)
This medicine contains 143 mg of lactose per film-coated tablet. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

(FEMMLUX® contains sodium)
This medicine contains less than 1 mmol (23 mg) sodium per film-coated tablet, that is to say essentially “sodium-free”.


If symptoms persist or worsen, consult your doctor.
Particularly when this medicine is used in children, medical advice should be sought.

NANOG® with food and drink: No interactions with food or beverages are known or have been reported.
There are insufficient data on the use of NANOG® in pregnant women. Therefore, it should not be used during pregnancy unless clearly necessary and only after the physician has assessed the benefit–risk balance.
It is not known whether simeticone is excreted in human breast milk. The excretion of simeticone in breast milk has not been studied in animals. The decision whether to continue or discontinue breastfeeding or to continue or discontinue treatment with simeticone should consider the benefits of breastfeeding for the child and the benefits of simeticone treatment for the woman.
No effects on the ability to drive or operate machinery have been observed with the use of NANOG®.
This emulsion contains parabens (used as preservatives), which may cause allergic reactions, including delayed allergic reactions.

This website is intended exclusively for residents of Portugal.
Date of Summary of Product Characteristics (SmPC) approval: July 2020.
Last revision: July 2020

TTell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
To date, no interactions between FEMMLUX® and food, drink or alcohol have been reported.

This website is intended exclusively for residents of Portugal.
Date of Summary of Product Characteristics (SmPC) approval: July 2020.
Last revision: July 2020

- Gastrointestinal symptoms (dyspeptic symptoms and diarrhoea).
- Allergic skin reactions (urticaria, pruritus and skin rash).
- Facial edema and peripheral edema.
- Hepatic reactions (including hepatitis, jaundice and abnormalities in liver function tests).

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via INFARMED, I.P.
By reporting side effects, you can help provide more information on the safety of this medicine.


This website is intended exclusively for residents of Portugal.
Date of Summary of Product Characteristics (SmPC) approval: July 2020.
Last revision: July 2020